Payment overview · 2025
General Payments
$395.51
15 reported records · 6 companies
Healthcare provider profile · identity verified
Benjamin Stevens, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MOUNTAIN HOME, AR · NPI 1215341656
Verified facts
What the public records show
CMS Open Payments records show Benjamin Stevens, M.D. received $395.51 in general payments during 2025 across 15 reported records.
AstraZeneca Pharmaceuticals LP accounted for 61.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Xarelto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $241.24 | 61.0% | 8 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $56.64 | 14.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.95 | 8.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.80 | 6.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.77 | 5.2% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $19.11 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $395.51 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $207.12 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $69.96 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $56.64 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.95 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $19.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 95 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
95 | 25 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
93 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 523 | 140 |
| Lisinopril | Lisinopril | 406 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 387 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 340 | 92 |
| Omeprazole | Omeprazole | 300 | 86 |
| Losartan Potassium | Losartan Potassium | 259 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 224 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 219 | 59 |
| Simvastatin | Simvastatin | 216 | 65 |
| Metformin Hcl | Metformin Hcl | 193 | 56 |
| Gabapentin | Gabapentin | 188 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 51 |
| Furosemide | Furosemide | 143 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 138 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 136 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 128 | 53 |
| Potassium Chloride | Potassium Chloride | 126 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 124 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 32 |
| Ozempic | Semaglutide | 115 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 108 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 31 |
| Allopurinol | Allopurinol | 105 | 30 |
| Carvedilol | Carvedilol | 104 | 36 |
| Trazodone Hcl | Trazodone Hcl | 104 | 26 |
| Meloxicam | Meloxicam | 99 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 95 | 25 |
| Eliquis | Apixaban | 93 | 23 |
| Bupropion Hcl Sr | Bupropion Hcl | 88 | 25 |
| Montelukast Sodium | Montelukast Sodium | 88 | 22 |
| Alendronate Sodium | Alendronate Sodium | 82 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 81 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 22 |
| Alprazolam | Alprazolam | 77 | 19 |
| Warfarin Sodium | Warfarin Sodium | 75 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 31 |
| Prednisone | Prednisone | 68 | 40 |
| Mirtazapine | Mirtazapine | 66 | 17 |
| Xarelto | Rivaroxaban | 62 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 16 |
| Clonazepam | Clonazepam | 60 | 14 |
| Tramadol Hcl | Tramadol Hcl | 58 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | 14 |
| Spironolactone | Spironolactone | 54 | 19 |
| Lovastatin | Lovastatin | 50 | 15 |
| Sertraline Hcl | Sertraline Hcl | 50 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 49 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 14 |
| Finasteride | Finasteride | 48 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 47 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | 15 |
| Topiramate | Topiramate | 41 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 40 | suppressed |
| Glipizide | Glipizide | 40 | 11 |
| Clonidine Hcl | Clonidine Hcl | 39 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Famotidine | Famotidine | 37 | suppressed |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Nitroglycerin | Nitroglycerin | 37 | 16 |
| Atenolol | Atenolol | 36 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 13 |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | 12 |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 27 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 15 |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Cefdinir | Cefdinir | 22 | 20 |
| Glimepiride | Glimepiride | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 13 |
| Diazepam | Diazepam | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 16 |
| Nystatin | Nystatin | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Lorazepam | Lorazepam | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 12 |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 14 |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Oxazepam | Oxazepam | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Cimetidine | Cimetidine | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $395.51 · 15 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, COMIRNATY, Dexcom G6 Transmitter, PREVNAR 20, SPRAVATO, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error